Olon, a company involved in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes, is expanding, and increasing production capacity, at its Mulazzano (Lodi, Italy) site. The expansion strategy is supported by an annual investment plan that will reach 100 million euros in 2023. “Olon was investing more than ever in these projects. We peaked with the level of investment in 2022, and in ...